Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

I'm a board-certified endocrinologist and , contrary to popular belief, choosing GLP-1 treatment isn't the ' easy way out.' ...

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...

The FDA has recalled thousands of Ziac blood pressure tablets after traces of a cholesterol drug were found during testing, ...

The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...

Medicare beneficiaries will see major pricing shifts as federal negotiations reshape how costly prescription drugs are paid ...

The company ended the third quarter of 2025 with $715 million in cash, a war chest deemed sufficient to fund both ongoing VANQUISH trials to completion. Research and development expenses jumped to $90 ...